A randomized clinical trial in patients with recent-onset arthritis to compare the efficacy of DMARD combination therapy including prednisone with combination therapy including adalimumab, a TNF-blocking agent.

Trial Profile

A randomized clinical trial in patients with recent-onset arthritis to compare the efficacy of DMARD combination therapy including prednisone with combination therapy including adalimumab, a TNF-blocking agent.

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs Adalimumab (Primary) ; Hydroxychloroquine; Methotrexate; Prednisone; Sulfasalazine
  • Indications Arthritis; Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms IMPROVED
  • Most Recent Events

    • 17 Jun 2017 Results (n=381) assessing association between baseline autoantibody profile and treatment response, presented at the 18th Annual Congress of the European League Against Rheumatism
    • 30 Oct 2013 Results for patients with early disease activity score remission presented at the 77th American College of Rheumatology and the 48th Annual Meeting of the Association of Rheumatology and Health Professionals.
    • 12 Nov 2010 Interim results were presented in an abstract presented at the 74th ACR/ARHP.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top